Why the study?
Does intravenous scopolamine affect cardiovascular dynamics in patients undergoing open-heart or major vascular operations under morphine-based anesthesia?
Does intravenous scopolamine affect cardiovascular dynamics in patients undergoing open-heart or major vascular operations under morphine-based anesthesia?
This study aims to determine the cardiovascular effects of scopolamine supplementation during morphine-based anesthesia for major cardiovascular surgeries.
Answers are grounded in this paper and cite their sources.
Cohort data leave scopolamine's hemodynamic effects during morphine anesthesia for major CV surgery unresolved; randomized trials needed before practice consideration.
Incomplete amnesia and awareness sometimes complicate morphine (0.5–3.0 mg/kg) or morphine (0.5–1.0 mg/kg)-nitrous oxide anesthesia.1 Scopolamine is often employed as a supplement during both of these techniques to prevent awareness. The cardiovascular effects of this drug during morphine anesthesia have not been investigated, however. In this study we measured the effects of intravenous administration of 0.5 mg scopolamine on cardiovascular dynamics during morphine-oxygen and morphine-nitrous oxide-oxygen anesthesia in 19 patients undergoing open-heart or major vascular operations.
No takes yet. Share an insight, caveat, or question.
Bennett et al. (1977) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: